{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Complete response (CR) rate is reported as the percentage of participants who achieved a CR.","groups":[{"description":"Participants will receive:\n\nBusulfan test dose of 25 mg/m\\^2 IV over 45 minutes between days -14 and -9; Fludarabine 30 mg/m\\^2/day IV over 30 minutes on days -7 to -3; Busulfan IV x 4 days on days -6 through -3 (dosage based on AUC of 4000 mmol/min based on pharmacokinetics determined from test dose); Allopurinol was given at discretion of treating physician; Rabbit antithymocyte globulin 1.5 mg/kg/day IV on days -6 and -5; Peripheral Blood Stem Cell Transplant (PBST) on Day 0 and +1; and methotrexate 5 mg/m\\^2/day IV on days +1, +3 and +6. G-CSF of 5mcg/kg/day SQ began daily on day +7 continuing until ANC \\> 1000/mL for 3 consecutive days.","id":"OG000","title":"Treatment"}],"populationDescription":"Due to study termination, data were not collected and the outcome measure was not analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 5.5 years","title":"Complete Response Rate","type":"SECONDARY"}